Vor Biopharma
49 hedge funds and large institutions have $151M invested in Vor Biopharma in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 18 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0% less ownership
Funds ownership: 4.15% → 4.14% (-0%)
16% less funds holding
Funds holding: 58 → 49 (-9)
20% less capital invested
Capital invested by funds: $188M → $151M (-$37.3M)
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$5.83M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.1M |
| 3 |
Millennium Management
New York
|
+$1.39M |
| 4 |
E
Ergoteles
New York
|
+$360K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.65M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.24M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$766K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$645K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$500K |
VOR Hedge Fund Activity: Q2 2022 in Review
49 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2022, worth a combined $151M — down 20% from $188M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of VOR and 10 opened new positions — a net loss of 8 holders — while 16 trimmed existing stakes and 11 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $5.83M. The largest seller was BlackRock, cutting an estimated $4.65M.
- 49 institutional investors held Vor Biopharma (VOR) as of Q2 2022, down from 58 in Q1 2022.
- Funds reported $151M of Vor Biopharma stock for Q2 2022, down 20% quarter-over-quarter.
- 10 funds opened new Vor Biopharma positions in Q2 2022 and 18 closed out, a net change of -8 holders.
- The largest Vor Biopharma buyer in Q2 2022 was Baker Bros. Advisors, an estimated $5.83M added.
- The largest Vor Biopharma seller in Q2 2022 was BlackRock, an estimated $4.65M sold.
Based on aggregated 13F filings for Q2 2022.